The HFpEF Summit is a biannual, two-day meeting bringing together internationally recognized leaders in the clinical, biological, and translational study of HFpEF. This summit focused on the latest ...

A team of scientists led by Northwestern Medicine investigators have uncovered new details about a deadly heart condition ...

The following is a summary of "Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

HealthDay News — In patients with heart failure with improved ejection fraction (EF), pharmacological therapy is rarely withdrawn, according to a study published online March 17 in Circulation.

Among iron-deficient patients with heart failure with reduced ejection fraction (HFrEF), receiving intravenous iron supplementation was found to be safe but resulted in mixed findings, according to a ...

EchoGo® Heart Failure remains the first and only AI platform capable of identifying HFpEF from a routine echocardiogram. The ...

This trial, the first randomized study on thoracentesis for pleural effusion in heart failure, found that adding routine ...

People with heart failure have long been advised to limit the amount of fluids they consume each day to help reduce congestion, or the buildup of fluid in the lungs and extremities, but that advice ...